Variation of anti-A and anti-B titers in group O potential blood donors: A pilot study.
ABO Blood-Group System
/ blood
Adult
Blood Donors
/ statistics & numerical data
Blood Group Incompatibility
/ blood
Blood Grouping and Crossmatching
/ statistics & numerical data
Female
Humans
Male
Military Personnel
/ statistics & numerical data
Pilot Projects
Retrospective Studies
Time Factors
Transfusion Reaction
/ blood
United States
/ epidemiology
Young Adult
Journal
The journal of trauma and acute care surgery
ISSN: 2163-0763
Titre abrégé: J Trauma Acute Care Surg
Pays: United States
ID NLM: 101570622
Informations de publication
Date de publication:
01 08 2021
01 08 2021
Historique:
pubmed:
19
5
2021
medline:
29
9
2021
entrez:
18
5
2021
Statut:
ppublish
Résumé
Resuscitation with fresh whole blood is vital to preserving life on the battlefield. Transfusing low titer O whole blood (LTOWB), defined as anti-A and anti-B titer levels of <1:256, is safe because LTOWB alleviates the risk for hemolytic transfusion reactions. Because of possible variations in titer levels over time, a study was needed using US Navy and Marine Corps personnel to assess how these titers change across two assessments. Retrospective data from group O marines and sailors (M = 25 years of age; range, 19-35 years) stationed in the San Diego region were acquired from the Armed Services Blood Program and the Composite Health Care System. Of 972 group O donors between January 2016 and November 2019, 55 donors with 2 samples were identified (N = 55). Analysis included contrasting rates of high (≥1:256) and low (<1:256) anti-A and anti-B titers on the initial and second blood tests, along with the time between testings. The average time between testing was 332 days (range, 35-1,121 days), which far exceeded the recommended 90-day interval (p < 0.00001). Only 45% met the 90-day recommendation. Titer status changed frequently, from low to high (anti-A, 18%; anti-B, 13%; LTOWB to not LTOWB, 21%) or from high to low (anti-A, 62%; anti-B, 78%; not LTOWB to LTOWB, 62%). Anti-A and anti-B titers change frequently enough to warrant testing immediately before deployment and even during deployment. The observed time elapsed between testing is unacceptably long. The present pilot study provides a foundation for a larger formal study to more fully characterize titer changes over repeated testing. Diagnostic test, level IV.
Sections du résumé
BACKGROUND
Resuscitation with fresh whole blood is vital to preserving life on the battlefield. Transfusing low titer O whole blood (LTOWB), defined as anti-A and anti-B titer levels of <1:256, is safe because LTOWB alleviates the risk for hemolytic transfusion reactions. Because of possible variations in titer levels over time, a study was needed using US Navy and Marine Corps personnel to assess how these titers change across two assessments.
METHODS
Retrospective data from group O marines and sailors (M = 25 years of age; range, 19-35 years) stationed in the San Diego region were acquired from the Armed Services Blood Program and the Composite Health Care System. Of 972 group O donors between January 2016 and November 2019, 55 donors with 2 samples were identified (N = 55). Analysis included contrasting rates of high (≥1:256) and low (<1:256) anti-A and anti-B titers on the initial and second blood tests, along with the time between testings.
RESULTS
The average time between testing was 332 days (range, 35-1,121 days), which far exceeded the recommended 90-day interval (p < 0.00001). Only 45% met the 90-day recommendation. Titer status changed frequently, from low to high (anti-A, 18%; anti-B, 13%; LTOWB to not LTOWB, 21%) or from high to low (anti-A, 62%; anti-B, 78%; not LTOWB to LTOWB, 62%).
CONCLUSIONS
Anti-A and anti-B titers change frequently enough to warrant testing immediately before deployment and even during deployment. The observed time elapsed between testing is unacceptably long. The present pilot study provides a foundation for a larger formal study to more fully characterize titer changes over repeated testing.
LEVEL OF EVIDENCE
Diagnostic test, level IV.
Identifiants
pubmed: 34001714
doi: 10.1097/TA.0000000000003274
pii: 01586154-202108002-00031
doi:
Substances chimiques
ABO Blood-Group System
0
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
S221-S225Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Eastridge BJ, Mabry RL, Seguin P, et al. Death on the battlefield (2001–2011): implications for the future of combat casualty care. J Trauma Acute Care Surg . 2012;73(6 Suppl 5):S431–S437.
Spinella PC, Perkins JG, Grathwohl KW, Beekley AC, Holcomb JB. Warm fresh whole blood is independently associated with improved survival for patients with combat-related traumatic injuries. J Trauma . 2009;66(Suppl 4):S69–S76.
Perkins JG, Cap AP, Spinella PC, Shorr AF, Beekley AC, Grathwohl KW, Rentas FJ, Wade CE, Holcomb JB; 31st Combat Support Hospital Research Group. Comparison of platelet transfusion as fresh whole blood versus apheresis platelets for massively transfused combat trauma patients (CME). Transfusion . 2011;51(2):242–252.
Borgman MA, Spinella PC, Perkins JG, Grathwohl KW, Repine T, Beekley AC, Sebesta J, Jenkins D, Wade CE, Holcomb JB. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma . 2007;63(4):805–813.
Zink KA, Sambasivan CN, Holcomb JB, Chisholm G, Schreiber MA. A high ratio of plasma and platelets to packed red blood cells in the first 6 hours of massive transfusion improves outcomes in a large multicenter study. Am J Surg . 2009;197:565–570.
Young PP, Cotton BA, Goodnough LT. Massive transfusion protocols for patients with substantial hemorrhage. Transfus Med Rev . 2011;25:293–303.
Joint Trauma System. Whole Blood Transfusion. 2018. Available at https://jts.amedd.army.mil/assets/docs/cpgs/JTS_Clinical_Practice_Guidelines_(CPGs)/Whole_Blood_Transfusion_15_May_2018_ID21.pdf . Accessed April 2020.
AABB. Standards for Blood Banks and Transfusion Services . 31 st ed. Bethesda, MD: AABB; 2018.
Berséus O. Effects on the anti-ABO titers of military blood donors from a predeployment vaccination program. J Trauma Acute Care Surg . 2017;82:S91–S95.
Sprogøe U, Yazer MH, Rasmussen MH, Antonsen B, Bistrup C, Assing K. Minimal variation in anti-A and -B titers among healthy volunteers over time: implications for the use of out-of-group blood components. J Trauma Acute Care Surg . 2017;82(6S Suppl 1):S87–S90.
Bailey JD, Fisher AD, Yazer MH, Howard JT, Corley JB, Miles EA, Cap AP. Changes in donor antibody titer levels over time in a military group O low-titer whole blood program. Transfusion . 2019;59(S2):1499–1506.
Cap AP, Beckett A, Benov A, et al. Whole blood transfusion. Mil Med . 2018;183(Suppl 2):44–51.
Joint Trauma System. Prehospital Blood Transfusion. 2020. Available at https://jts.amedd.army.mil/assets/docs/cpgs/Prehospital_Blood_Transfusion_30_Oct_2020_ID82.pdf . Accessed March 2021.
Fisher AD, Miles EA, Broussard MA, Corley JB, Knight R, Remley MA, Cap AP, Gurney JM, Shackelford SA. Low titer group O whole blood resuscitation: military experience from the point of injury. J Trauma Acute Care Surg . 2020;89(4):834–841.
McGinity AC, Zhu CS, Greebon L, et al. Prehospital low-titer cold-stored whole blood: philosophy for ubiquitous utilization of O-positive product for emergency use in hemorrhage due to injury. J Trauma Acute Care Surg . 2018;84(6S Suppl 1):S115–S119.
Seheult JN, Triulzi DJ, Alarcon LH, Sperry JL, Murdock A, Yazer MH. Measurement of haemolysis markers following transfusion of uncrossmatched, low-titre, group O+ whole blood in civilian trauma patients: initial experience at a level 1 trauma centre. Transfus Med . 2017;27(1):30–35.
Stubbs JR, Zielinski MD, Jenkins D. The state of the science of whole blood: Lessons learned at Mayo Clinic. Transfusion . 2016;56 Suppl 2(Suppl 2):S173–S181.
Berséus O, Boman K, Nessen SC, Westerberg LA. Risks of hemolysis due to anti-A and anti-B caused by the transfusion of blood or blood components containing ABO-incompatible plasma. Transfusion . 2013;53(Suppl 1):114S–123S.
Yazer MH, Dunbar NM, Bub CB, et al. Comparison of titer results obtained using immediate spin one-dilution techniques to a reference method. Transfusion . 2019;59(S2):1512–1517.